Evidence map›Paper›PMID 35386741›Full record

ArticleJournal of scleroderma and related disorders2021

Refractory eosinophilic fasciitis successfully treated with infliximab: A case report.

Paulina Śmigielska, Justyna Czarny, Jacek Kowalski, Aleksandra Wilkowska, Roman J Nowicki

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of scleroderma and related disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. [Eosinophilic dermatoses].Dermatologie (Heidelberg, Germany) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Paulina ŚmigielskaDepartment of Dermatology, Venereology and Allergology, Medical University of Gdańsk, Gdańsk, Poland.ORCID https://orcid.org/0000-0001-8327-7694
Justyna CzarnyDepartment of Dermatology, Venereology and Allergology, Medical University of Gdańsk, Gdańsk, Poland.
Jacek KowalskiDepartment of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland.
Aleksandra WilkowskaDepartment of Dermatology, Venereology and Allergology, Medical University of Gdańsk, Gdańsk, Poland.
Roman J NowickiDepartment of Dermatology, Venereology and Allergology, Medical University of Gdańsk, Gdańsk, Poland.ORCID https://orcid.org/0000-0003-4768-1387
Gdańsk Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eosinophilic fasciitis is a rare connective tissue disease of unknown etiology. Therapeutic options include high-dose corticosteroids and other immunosuppressive drugs. We present a typical eosinophilic fasciitis case, which did not respond to first-line treatment, but improved remarkably after infliximab administration. This report demonstrates that in case of initial treatment failure, infliximab might be a relatively safe and effective way of eosinophilic fasciitis management.

Indexed as

Eosinophilic fasciitisinfliximabmonoclonal antibodyscleroderma-like disorders

Identifiers

PMID35386741
PMCPMC8892936
OpenAlexW3139970855

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.